15 October 2024
15 October 2024
Bexicaserin is currently under evaluation in a global Phase III clinical programme known as DEEp SEA.
The company plans to apply for FDA approval for its DMD cell therapy, deramiocel, by the end of 2024.
The collaboration aims to support evidence-based interventions that promote equitable healthcare access.
As a major report highlights the challenges of a struggling NHS, the call for preventative care is growing in the UK. With a taskforce investigating ways of integrating preventative health services into communities, and a powerful case finding solution now available to put proactive care into action, we explore the latest in preventative health innovation.
Data from the Rainbowfish trial was presented at the World Muscle Society (WMS) Congress 2024 in Prague, Czech Republic.
The NMPA approval is based on the outcomes of Phase II DESTINY-Lung02 and DESTINY-Lung05 trials.
Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.
Digital assessment technologies continue to hold the potential to revolutionise pro-cognitive trials in schizophrenia. These advancements could continue to streamline data collection, improve trial accuracy and ultimately accelerate the development of effective treatments to address unmet patient need.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
